LI
APLS

Leap Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Leap Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,700
Closed -$306K – 422
2019
Q3 		$306K Buy
+12,700
New +$350K 0.15% 225

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Leap Investments's APLS Position: Q4 2019 in Review

Leap Investments sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 12,700 shares — an estimated $306K sold.

Leap Investments first reported a position in APLS in Q3 2019 and held it in 1 quarter. The position peaked at $306K in Q3 2019. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • Leap Investments reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 12,700 Apellis Pharmaceuticals shares in Q4 2019, an estimated $306K.
  • Leap Investments first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Leap Investments's Apellis Pharmaceuticals position peaked at $306K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.